Compare Stocks

Guardian Capital Group Limited, together with its subsidiaries, operates as a diversified financial services company in Canada, the United Kingdom, the United States, and the Caribbean. It manages institutional assets for pension plans, insurers, foundations, endowments, third-party mutual funds, and ETFs; and provides private wealth management services to individuals, families, and charitable organizations. The company also offers trust and corporate administration, investment management, and banking services for international clients; and an integrated wealth management platform for financial advisors to deliver professional advice on mutual funds, securities, and insurance. In addition, it engages in the sale of life insurance products, mutual funds, and other securities. Guardian Capital Group Limited was founded in 1962 and is headquartered in Toronto, Canada.

EGShares India Small Cap exchange-traded fund (the Fund) is an exchange-traded fund (ETF). The Fund seeks investment results that generally correspond (before fees and expenses) to the price and yield performance of the Indxx India Small Cap Index. The index is a free-float market capitalization weighted stock market index consists of a representative sample of Indian companies that Indxx LLC determines to be the representative of small market cap companies in India. It invests in a range of sectors, such as financials, consumer goods, industrials, health care, utilities, basic materials, consumer services, oil and gas, technology, and telecommunications. Its investment adviser is ALPS Advisors, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.